Skip to main content

Table 1 General characteristics of kidney transplant recipients

From: Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients

Number of Patients

280 (100)

   Group 1 (less than 30 days after transplantation)

102 (36.4)

   Group 2 (1 to 6 months after transplantation)

73 (26)

   Group 3 (> 6 months after transplantation)

105 (37.5)

Gender

 

   Male

163 (58.2)

Race

 

   White

187 (66.7)

   Non-white

93 (33.2)

Primary renal disease

 

   Indeterminate

137 (48.9)

   Hypertension

61 (21.7)

   Glomerulonephritis

44 (15.7)

   Diabetes Mellitus

11 (3.9)

   Others

27 (9.6)

Pre transplant treatment

 

   Hemodialysis

262 (93.5)

   CAPD

12 (4.2)

   Conservative

6 (2.1)

Kidney donor

 

   HLA I and II

160 (57.1)

   HLA III and deceased donor

120 (42.8)

Immunosuppressive drugs **

 

   Mycophenolate mofetil

59 (33.1)

   OKT3/Thymoglobulin®

13 (7.3)

   Methylprednisolone pulse

58 (32.5)

Surgical reexploration

14 (5)

Post-transplantation dialysis

46 (16.4)

Serology

 

   Hepatitis C virus

31 (11)

   Hepatitis B virus

7 (2.5)

Post-transplantation antimicrobial drugs **

117 (65.7)

Vancomycin **

11 (6.1)

Ganciclovir **

18 (10.1)

  1. ** Immunosuppressive drugs, post-transplantation antimicrobial drugs, vancomycin and ganciclovir: just for groups 2 and 3.
  2. CAPD = chronic ambulatory peritoneal dialysis; HLA I = identical human leukocyte antigen;
  3. HLA II = haplo-identical human leukocyte antigen; HLA III = distinct human leukocyte antigen;
  4. Values are expressed as N (%).